Advertisement
Canada markets close in 2 hours 31 minutes

  • S&P/TSX

    21,847.22
    +118.67 (+0.55%)
     

  • S&P 500

    5,054.55
    +36.16 (+0.72%)
     

  • DOW

    38,153.02
    +249.73 (+0.66%)
     

  • CAD/USD

    0.7308
    +0.0027 (+0.37%)
     

  • CRUDE OIL

    79.22
    +0.22 (+0.28%)
     

  • Bitcoin CAD

    80,916.46
    +2,880.46 (+3.69%)
     

  • CMC Crypto 200

    1,271.70
    +0.95 (+0.07%)
     

  • GOLD FUTURES

    2,309.60
    -1.40 (-0.06%)
     

  • RUSSELL 2000

    2,006.75
    +26.52 (+1.34%)
     

  • 10-Yr Bond

    4.5910
    -0.0040 (-0.09%)
     

  • NASDAQ

    15,794.34
    +188.86 (+1.21%)
     

  • VOLATILITY

    14.91
    -0.48 (-3.12%)
     

  • FTSE

    8,172.15
    +50.91 (+0.63%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • CAD/EUR

    0.6816
    +0.0023 (+0.34%)
     
MARKETS LIVE BLOG:

STOCKS CLIMB AS RATE-HIKE FEARS FADE, WITH APPLE ON DECK

Bitcoin rebounds to US$59,000 following record ETFs outflow

Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024

Business Wire
·1 min read

LEXINGTON, Mass., April 18, 2024--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that the company will host a Research & Development Day from 9:00a.m. to 1:00p.m. ET on Thursday, April 25, 2024 in New York City.

Aldeyra will provide an in-depth review of pipeline programs, and the event will feature presentations from members of the Aldeyra senior leadership team.

A live audio webcast and slide presentation will be accessible from the "Investors & Media" section of the Aldeyra website at https://ir.aldeyra.com/ for 90 days following the event.

About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX‑629, ADX‑246, ADX‑248, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240418015056/en/

Contacts

Investor & Media:
David Burke
Tel: (917) 618-2651
investorrelations@aldeyra.com